Quest Diagnostics stock
Price history
+40.54% over the period1 year: from $186.19 (November 17, 2025) to $261.68 (November 16, 2026), +40.54%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $261.68 |
| October 30, 2026 | $251.82 |
| September 30, 2026 | $233.07 |
| August 31, 2026 | $240.30 |
| July 31, 2026 | $233.01 |
| June 30, 2026 | $211.95 |
| May 29, 2026 | $194.90 |
| April 30, 2026 | $194.20 |
| March 31, 2026 | $195.98 |
| February 27, 2026 | $211.91 |
| January 30, 2026 | $187.03 |
| December 31, 2025 | $173.53 |
| November 28, 2025 | $189.18 |
| November 17, 2025 | $186.19 |
At a glance
The company
Provides diagnostic testing and information services including clinical laboratory testing, pathology, drug testing and risk assessment for healthcare providers, payers, employers and insurers
Latest results
Quarter to September 30, 2026 · EPS $3.00 (estimate $2.87)
Dividend
TickerLandia's take on Quest Diagnostics
- Pricier than usual relative to earnings: P/E on the latest fiscal year 30 vs a median of 18 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 26 vs 36 (−28%) in a group of 9.
- Strong point: Market momentum (85/100 in its group). Weak point: Financial strength (38/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−0.12% from the 52-week high
Analysts · 17 analysts
Average target$257.27−1.69% vs. price
Buy 9 · Hold 8 · Sell 0 · Buy
TickerLandia Fingerprint: Quest Diagnostics
Compared with similar companies: very low risk and very strong momentum.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow37
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 14.7 38 P/E (trailing 12 months) 25.9 23 Forward P/E 21.7 50 Price/book 3.74 44 Price/sales 2.41 28 Profitabilityaverage48
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 33.2% 28 Net margin 9.5% 50 ROE 15.3% 65 ROA 6.6% 61 Operating margin 14.9% 35 Earnings stabilityaverage54
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.6% 46 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthhigh64
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +3.74% 57 Revenue growth (year over year) +10.00% 67 Earnings growth (year over year) +28.70% 69 Financial strengthlow38
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.80 28 Current ratio 1.70 50 Interest coverage 5.79 40 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.74 34 Dividendhigh65
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 33.7% 59 Consecutive dividend years 23 years 74 Dividend yield 1.3% 63 Market momentumvery strong85
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +13.43% 80 Relative strength (6 months) +33.91% 89 Distance from 200-day average +20.35% 89 1-year return +38.39% 80 Riskvery low10
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 11.9% 3 Volatility (60 days) 22.0% 15 Beta (1 year) −0.06 13
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Quest Diagnostics is pricier than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Quest Diagnostics's P/E today is 29.9, above the median of its last 10 fiscal years (18.2; between 11.1 and 20.4 from 2016 to 2025). Quest Diagnostics's P/E (trailing 12 months): 25.9, −28% against the median of a group of 9 similar companies (36.1).
Compared with 9 similar companies
| Metric | Quest Diagnostics | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 25.9 | Low | |
| Forward P/E | 21.7 | Middle | |
| Operating margin | 14.9% | Middle | |
| ROE | 15.3% | Middle | |
| Debt/equity | 0.80 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Quest Diagnostics. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$3.1B
Latest quarter · Q3 2026
Net income
$312M
Latest quarter · Q3 2026
Quarterly net margin
10.1%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $28.56B
- P/E
- 25.9
- EPS
- $10.04
- Volume
- 648.93K
- Daily trading
- €217.95M
- Dividend yield
- 1.29%
How Quest Diagnostics is changing
All resultsRevenue grew 3.2% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 115% of net income
Shares outstanding down 16.9% in 5 years
Returns
Quest Diagnostics returns with dividends
$1,000 invested in Quest Diagnostics 5 years ago, on November 16, 2021, would be worth $1,947 today with dividends reinvested: +94.74% in total, +14.26% per year. On price alone it would be $1,768 (+76.81%).
| Period | Quest Diagnostics | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +11.35% | −3.12% | $1,114 |
| 6 months | +40.23% | +2.07% | $1,402 |
| Year to date | +50.80% | +10.46% | $1,508 |
| 1 year | +42.90% | +13.33% | $1,429 |
| 3 years | +105.27% | +67.73% | $2,053 |
| 5 years | +94.74% | +60.86% | $1,947 |
| 10 years | +275.95% | +247.35% | $3,759 |
Over the last 6 months it has done better than 78% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Quest Diagnostics: technical analysis
Quest Diagnostics is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is at its all-time closing high.
- Trend
- Upward
- RSI (14 sessions)
- 71
- Above 70: a strong rise in a short time
- vs 200-session average
- +21.10%
Active signals
New 52-week high.
RSI above 70: the stock has risen a lot in a short time.
Support and resistance
Price areas where Quest Diagnostics has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$261.68
- Support$248.01−5.22%2 touches, last on September 21, 2026
- Support$225.51−13.82%3 touches, last on October 21, 2026
- Support$213.35−18.47%2 touches, last on February 27, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- −0.07
- Volatility (60 sessions, annualised)
- 21.9%
- Largest fall in the last year
- −11.94%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Quest Diagnostics: seasonality
Average monthly price change over 30 years
Over the last 30 years, the strongest month for Quest Diagnostics has been April: +6.80% on average, positive in 20 years out of 30. The weakest has been September: −0.68% on average, positive in 12 years out of 30. November, the current month, has been positive in 24 years out of 29 (+3.36% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.56% | −0.41% | 14 of 30 |
| February | +0.19% | −0.63% | 13 of 30 |
| March | +1.98% | +3.16% | 20 of 30 |
| April | +6.80% | +2.78% | 20 of 30 |
| May | +2.86% | +2.40% | 22 of 30 |
| June | +2.79% | +1.83% | 20 of 30 |
| July | −0.57% | −2.51% | 13 of 30 |
| August | −0.18% | +0.34% | 17 of 30 |
| September | −0.68% | −1.47% | 12 of 30 |
| October | −0.06% | −0.06% | 15 of 30 |
| November | +3.36% | +4.99% | 24 of 29 |
| December | +2.35% | +0.85% | 20 of 29 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Quest Diagnostics and its competitors
Based in Secaucus, New Jersey, and operating since 1967, the company runs a network of laboratories and patient service centers that handles routine and advanced clinical tests, anatomic pathology, and genetic screening for prenatal care. Its services reach physicians, hospitals, patients, employers, insurers, and government agencies across the US, with brands including AmeriPath, Dermpath Diagnostics, ExamOne and Quanum alongside its own name. Workplace drug testing, toxicology, and underwriting support for life insurers are among its offerings, and it also develops in vitro diagnostic tests.
- Headquarters
- Secaucus, United States
- Employees
- 60,000
- Founded
- 1967
- Chief executive
- James Davis
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Quest DiagnosticsDGX | $28.56B | 14.9% | 25.9 | +40.23% |
| Labcorp HoldingsLH | $30.08B | 11.2% | 30.4 | +48.09% |
| IlluminaILMN | $31.3B | 19.1% | 36.1 | +40.14% |
| Mettler-Toledo InternationalMTD | $34.59B | 27.8% | 37.7 | +67.76% |
| Guardant HealthGH | $20.52B | -39.4% | — | +52.78% |
| Medpace HoldingsMEDP | $19.12B | 21.4% | 38.0 | +57.36% |
Same industry or related industries, similar size. Compare Quest Diagnostics with its competitors · Full profile
